317 related articles for article (PubMed ID: 23639651)
1. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
2. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
3. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
4. Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors.
Ettari R; Bonaccorso C; Micale N; Heindl C; Schirmeister T; Calabrò ML; Grasso S; Zappalà M
ChemMedChem; 2011 Jul; 6(7):1228-37. PubMed ID: 21506279
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Proteasome Inhibitors from an Enaminone Library.
Elliott ML; Thomas K; Kennedy S; Koduri ND; Hussaini RS; Sheaff RJ
Chem Biol Drug Des; 2015 Sep; 86(3):322-32. PubMed ID: 25494709
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
[TBL] [Abstract][Full Text] [Related]
7. α- and β-hydrazino acid-based pseudopeptides inhibit the chymotrypsin-like activity of the eukaryotic 20S proteasome.
Bordessa A; Keita M; Maréchal X; Formicola L; Lagarde N; Rodrigo J; Bernadat G; Bauvais C; Soulier JL; Dufau L; Milcent T; Crousse B; Reboud-Ravaux M; Ongeri S
Eur J Med Chem; 2013; 70():505-24. PubMed ID: 24185380
[TBL] [Abstract][Full Text] [Related]
8. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.
Maccari R; Ettari R; Adornato I; Naß A; Wolber G; Bitto A; Mannino F; Aliquò F; Bruno G; Nicolò F; Previti S; Grasso S; Zappalà M; Ottanà R
Bioorg Med Chem Lett; 2018 Feb; 28(3):278-283. PubMed ID: 29292224
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
[TBL] [Abstract][Full Text] [Related]
10. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
12. C-terminal trans,trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors.
Franceschini C; Trapella C; Calia R; Scotti A; Sforza F; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1034-9. PubMed ID: 22871133
[TBL] [Abstract][Full Text] [Related]
13. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
[TBL] [Abstract][Full Text] [Related]
14. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new series of amides as non-covalent proteasome inhibitors.
Scarbaci K; Troiano V; Micale N; Ettari R; Tamborini L; Di Giovanni C; Cerchia C; Grasso S; Novellino E; Schirmeister T; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Apr; 76():1-9. PubMed ID: 24561716
[TBL] [Abstract][Full Text] [Related]
16. New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.
Neilsen PM; Pehere AD; Pishas KI; Callen DF; Abell AD
ACS Chem Biol; 2013 Feb; 8(2):353-9. PubMed ID: 23190346
[TBL] [Abstract][Full Text] [Related]
17. Peptido sulfonyl fluorides as new powerful proteasome inhibitors.
Brouwer AJ; Jonker A; Werkhoven P; Kuo E; Li N; Gallastegui N; Kemmink J; Florea BI; Groll M; Overkleeft HS; Liskamp RM
J Med Chem; 2012 Dec; 55(24):10995-1003. PubMed ID: 23170994
[TBL] [Abstract][Full Text] [Related]
18. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
19. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
20. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.
Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G
ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
